Evaluation of the effects of androgenic Chinese herbal medicines on androgen receptors and tumor growth in experimental prostate cancer models
Zhen-Biao Zhang,Siu-Po Ip,William Chi Cho,Zhen Hu,Yan-Feng Huang,Dan-Dan Luo,Yan-Fang Xian,Zhi-Xiu Lin
DOI: https://doi.org/10.1016/j.jep.2020.113058
IF: 5.195
2020-10-01
Journal of Ethnopharmacology
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Ethnopharmacological relevance</h3><p>Many prostate cancer (PCa) patients in Mainland China and other Asian countries often use Chinese herbal medicines as an adjuvant treatment while receiving Western medicines. However, concerns have been raised about the potential herb-drug interaction when using herbal medicines containing phytoandrogens.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Aim of the study</h3><p>This study aimed to investigate the effects of the selected 21 Chinese herbal medicines on the proliferation and tumor growth using the relevant <em>in vitro</em> and <em>in vivo</em> models of PCa.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Materials and methods</h3><p>After treatment of LNCaP and 22Rv1 cells with different concentrations of 70% ethanol extracts of the 21 selected herbal medicines for 48 h, the proliferative activity, the effects on androgen receptor (AR) and prostate specific antigen (PSA) were determined. The anti-tumor effects of the 21 herbs on PCa growth were also investigated on a subcutaneous mouse model of PCa.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>The results showed that Epimedii Folium (EF) and Codonopsis Radix (CNR) could significantly increase the cell viability in LNCaP cells (<em>p</em> < 0.05 for both) and 22Rv1 cells (<em>p</em> < 0.05 for both), protein expressions of AR in LNCaP cells (<em>p</em> < 0.05 for both) and 22Rv1 cells (<em>p</em> < 0.05 for both), and PSA (<em>p</em> < 0.05 for both) in LNCaP cells. EF, CNR, and Cistanches Herba (CCH) markedly accentuated the tumor growth (<em>p</em> < 0.05 for three drugs) and AR expression (<em>p</em> < 0.05 for three herbs) in tumor tissues. On the other hand, treatment with Astragali Radix (AGR), Chuanxiong Rhizoma (CXR) and Bruceae Fructus (BF) significantly inhibited the cell viability in LNCaP cells (<em>p</em> < 0.05, <em>p</em> < 0.05 and <em>p</em> < 0.001, respectively) and in 22Rv1 cells (<em>p</em> < 0.05, <em>p</em> < 0.05 and <em>p</em> < 0.001, respectively), and the protein expression of AR in LNCaP cells (<em>p</em> < 0.05 for three herbs) and 22Rv1 cells (<em>p</em> < 0.05, <em>p</em> < 0.05 and <em>p</em> < 0.001, respectively), and the protein expression of PSA (<em>p</em> < 0.05 for three herbs) in LNCaP cells, as well as tumor growth (<em>p</em> < 0.05 for three herbs) and the AR expression (<em>p</em> < 0.05 for AGR and CXR, <em>p</em> < 0.001 for BF) in tumor tissues.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>Our results revealed that AGR, CXR and BF suppressed the PCa development via inhibition of AR expression, while EF, CNR and CCH promoted the development and progression of PCa via enhancement of AR expression. The results strongly suggest that caution should be exercised when using androgenic Chinese herbal medicines in PCa patients.</p>
pharmacology & pharmacy,chemistry, medicinal,integrative & complementary medicine,plant sciences